<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00745420</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN0601</org_study_id>
    <secondary_id>U01HL069294</secondary_id>
    <secondary_id>5U24CA076518</secondary_id>
    <nct_id>NCT00745420</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)</brief_title>
  <acronym>SCURT</acronym>
  <official_title>Unrelated Donor Reduced Intensity Bone Marrow Transplant for Children With Severe Sickle Cell Disease (BMT CTN #0601)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sickle Cell Disease Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease
      that can cause organ damage, stroke, and intense pain episodes. A blood stem cell transplant
      is a treatment option for someone with a severe form of the disease. Prior to undergoing a
      transplant, people typically receive a conditioning regimen of high doses of chemotherapy and
      other medications to prepare the body to accept the transplant. A conditioning regimen that
      uses lower doses of chemotherapy and medications may be safer for transplant recipients. This
      study will evaluate the safety and effectiveness of blood stem cell transplants, using bone
      marrow from unrelated donors, in children with severe SCD who receive a reduced intensity
      conditioning regimen prior to the transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SCD is an inherited blood disorder. Symptoms include anemia, infections, organ damage, and
      intense episodes of pain, also called &quot;sickle cell crises.&quot; SCD is caused by an abnormal type
      of hemoglobin, which is a protein inside red blood cells that carries oxygen to vital organs,
      such as the brain, heart, lungs, and kidneys. Defective hemoglobin damages red blood cells.
      The damaged cells, in turn, can block blood flow in vessels and block oxygen and nutrients
      from reaching organs. For people with severe forms of SCD, one treatment option is a bone
      marrow transplant, which may correct the abnormal blood cell production problem. In most
      cases, bone marrow transplants are performed in people who have a healthy sibling with the
      same tissue type. If people do not have a sibling with the same tissue type, it is possible
      for them to receive a blood stem cell transplant from an unrelated donor through bone marrow
      transplant .

      Traditionally, people with SCD who are undergoing a bone marrow transplant receive high doses
      of chemotherapy and medications before the transplant as part of the conditioning regimen to
      prepare their immune system to accept the donor cells. Participants will experience fewer
      side effects with a reduced intensity conditioning regimen than with a more intense
      conditioning regimen. The purpose of this study is to determine the safety and effectiveness
      of blood stem cell transplants, using bone marrow from unrelated donors, in children with
      severe SCD who receive a reduced intensity conditioning regimen before the transplant.
      Specifically, researchers will evaluate whether the reduced intensity conditioning regimen is
      successful in allowing donor cells to settle and grow successfully, in preventing the
      production of SCD-damaged red blood cells, and in limiting SCD-related organ damage.

      This study will enroll children with severe SCD who lack a sibling with the same tissue type
      who can serve as their donor. Participants will attend a study visit prior to the transplant
      to undergo a blood collection, neurocognitive testing to measure learning and brain function,
      and magnetic resonance angiogram (MRA) and magnetic resonance imaging (MRI) scans.
      Questionnaires to assess quality of life will also be completed. Twenty-two days before the
      transplant, participants will begin receiving a reduced intensity conditioning regimen of
      chemotherapy and medications to prepare them for the transplant. Eight days before the
      transplant, participants will be admitted to the hospital and will continue the conditioning
      regimen. Participants will then receive the bone marrow transplant. After the transplant,
      participants will receive immunosuppression medications for at least 6 months to prevent
      graft-versus-host disease (GVHD), which may occur if the immune cells from the donated bone
      marrow attacks the body of the recipient. One week after the transplant, participants will
      receive granulocyte-colony-stimulating factor (G-CSF), which is a natural protein that
      increases the white blood cell count and helps protect the body against infections.
      Participants will receive G-CSF until their white blood cell level is normal again.
      Participants will remain in the hospital and be closely monitored for signs of infection or
      other complications until study researchers feel it is safe for them to return home.

      After leaving the hospital, participants will attend study visits weekly during Weeks 1 to 8,
      at Day 60, weekly during Weeks 9 to 14, at Day 100, at Month 6, and at Years 1 and 2. At all
      study visits, a blood collection, medical history review, and physical exam will occur. In
      addition, at Day 100, Month 6, and Years 1 and 2, questionnaires to assess quality of life
      will be completed. At select visits the following procedures will also occur: lung function
      testing, heart function testing, MRA and MRI scans, and neurocognitive testing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Event-Free Survival (EFS)</measure>
    <time_frame>2 years</time_frame>
    <description>EFS is defined as percentage of participants that have not had an event. Primary or secondary graft rejection, disease recurrence, or death will count as events for this endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>OS is defined as the percentage of participants that have not died.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil and Platelet Recovery</measure>
    <time_frame>Up to 100 days</time_frame>
    <description>Time to neutrophil recovery is defined as the time of the first of three measurements on consecutive days where the patient has an absolute neutrophil count of &gt;= 500/uL following conditioning regimen induced nadir. Time to platelet recovery is defined as the time of the first of three measurements on consecutive days where the patient has achieved a platelet count &gt; 50,000/uL and is platelet transfusion independent for a minimum of seven days following conditioning regimen induced nadir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Rejection</measure>
    <time_frame>1 year</time_frame>
    <description>Primary graft rejection is defined as the presence of less than 20% donor cells as assessed by peripheral blood or bone marrow chimerism assays on or after Day 42. Secondary graft rejection is defined as the presence of less than 20% donor derived hematopoietic cells in peripheral blood or bone marrow that occurs after prior evidence of 20% or greater donor cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Acute Graft-vs-Host-Disease (GVHD)</measure>
    <time_frame>100 days</time_frame>
    <description>Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:
Skin stage:
0: No rash
Rash &lt;25% of body surface area
Rash on 25-50% of body surface area
Rash on &gt; 50% of body surface area
Generalized erythroderma with bullous formation
Liver stage (based on bilirubin level)*:
0: &lt;2 mg/dL
2-3 mg/dL
3.01-6 mg/dL
6.01-15.0 mg/dL
&gt;15 mg/dL
GI stage*:
0: No diarrhea or diarrhea &lt;500 mL/day
Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD
Diarrhea 1000-1499 mL/day
Diarrhea &gt;1500 mL/day
Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.
GVHD grade:
0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Chronic GVHD</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>Chronic GVHD is defined per NIH 2005 Consensus Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Chronic GVHD by Severity</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>Chronic GVHD severity is defined per NIH 2005 Consensus Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Posterior Reversible Encephalopathy Syndrome (PRES)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 100 in Participant Reported Health-Related Quality of Life (HRQL)</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>HRQL will be assessed using the Self-Esteem, General Health Perception, and Change in Health subscales of the Child Health Questionnaire (CHQ Child Form 87). The changes in participant reported scores on these HRQL subscales from a pre-transplant baseline assessment to day 100 post-transplant will be evaluated. Each subscale is scored is scored in the range 0-100, with higher scores indicating better health and well-being. Therefore, a negative mean change in score denotes worsening HRQL score and positive mean change in score denotes an improved HRQL score over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 100 in Parent Proxy Reported Health-Related Quality of Life (HRQL)</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>HRQL will be assessed using the Self-Esteem, General Health Perception, and Change in Health subscales of the Child Health Questionnaire (CHQ Child Form 87). The changes in parent proxy reported scores on these HRQL subscales from a pre-transplant baseline assessment to day 100 post-transplant will be evaluated. Each subscale is scored is scored in the range 0-100, with higher scores indicating better health and well-being. Therefore, a negative mean change in score denotes worsening HRQL score and positive mean change in score denotes an improved HRQL score over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 180 in Participant Reported Health-Related Quality of Life (HRQL)</measure>
    <time_frame>180 days post-transplant</time_frame>
    <description>HRQL will be assessed using the Self-Esteem, General Health Perception, and Change in Health subscales of the Child Health Questionnaire (CHQ Child Form 87). The changes in participant reported scores on these HRQL subscales from a pre-transplant baseline assessment to day 180 post-transplant will be evaluated. Each subscale is scored is scored in the range 0-100, with higher scores indicating better health and well-being. Therefore, a negative mean change in score denotes worsening HRQL score and positive mean change in score denotes an improved HRQL score over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 180 in Parent Proxy Reported Health-Related Quality of Life (HRQL)</measure>
    <time_frame>180 days post-transplant</time_frame>
    <description>HRQL will be assessed using the Self-Esteem, General Health Perception, and Change in Health subscales of the Child Health Questionnaire (CHQ Child Form 87). The changes in parent proxy reported scores on these HRQL subscales from a pre-transplant baseline assessment to day 180 post-transplant will be evaluated. Each subscale is scored is scored in the range 0-100, with higher scores indicating better health and well-being. Therefore, a negative mean change in score denotes worsening HRQL score and positive mean change in score denotes an improved HRQL score over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 1 Year in Participant Reported Health-Related Quality of Life (HRQL)</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>HRQL will be assessed using the Self-Esteem, General Health Perception, and Change in Health subscales of the Child Health Questionnaire (CHQ Child Form 87). The changes in participant reported scores on these HRQL subscales from a pre-transplant baseline assessment to 1 year post-transplant will be evaluated. Each subscale is scored is scored in the range 0-100, with higher scores indicating better health and well-being. Therefore, a negative mean change in score denotes worsening HRQL score and positive mean change in score denotes an improved HRQL score over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 1 Year in Parent Proxy Reported Health-Related Quality of Life (HRQL)</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>HRQL will be assessed using the Self-Esteem, General Health Perception, and Change in Health subscales of the Child Health Questionnaire (CHQ Child Form 87). The changes in parent proxy reported scores on these HRQL subscales from a pre-transplant baseline assessment to 1 year post-transplant will be evaluated. Each subscale is scored is scored in the range 0-100, with higher scores indicating better health and well-being. Therefore, a negative mean change in score denotes worsening HRQL score and positive mean change in score denotes an improved HRQL score over time.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bone Marrow Transplant with GVHD Prophylaxis Regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>The stem cell transplant preparative regimen is listed below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.
Alemtuzumab: Children weighing 10 kg or more will receive 10 mg, 15 mg, and 20 mg intravenously (IV) on Days -21, -20, and -19, respectively
Fludarabine: 30 mg/m^2/day IV on Days -8 through -4
Melphalan: 140 mg/m^2 IV on Day -3
Rest on Days -2 and -1
Transplant occurs on Day 0
GVHD prophylaxis: Tacrolimus or cyclosporine beginning Day -3, methotrexate (7.5 mg/m2/day) Day 1, 3 and 6 and methylprednisolone/prednisone on Day +7 to +28 followed by a taper if there is no GVHD</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Bone Marrow Transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SCD (genotype hemoglobin SS disease [Hb SS], genotype hemoglobin SC disease
             [HbSC],sickle ß°[Sß°] thalassemia, or sickle ß^+[Sß^+]thalassemia) with one or more of
             the following:

               1. Patients must have symptomatic SCD (genotype Hb SS, Hb SC, Sß° thalassemia or Sß+
                  thalassemia), AND have 1 or more of the following clinical complications:(i)
                  Clinically significant neurologic event (stroke) or any neurologic deficit
                  lasting more than 24 hours that is accompanied by an infarct on cerebral MRI; OR
                  (ii) patients who have a Transcranial Doppler (TCD) velocity that exceeds 200
                  cm/sec by the non-imaging technique (or TCD measurement greater than 185 cm/sec
                  by the imaging technique) measured at a minimum of 2 separate occasions one month
                  or more apart; OR,

               2. Minimum of two episodes of acute chest syndrome in the 2 years before study
                  entry, defined as new pulmonary alveolar consolidation involving at least one
                  complete lung segment (associated with acute symptoms including fever, chest
                  pain, tachypnea, wheezing, rales, or cough that is not attributed to asthma or
                  bronchiolitis) despite adequate supportive care measures

               3. History of 3 or more severe pain events per year in the 2 years before study
                  entry

          -  Lansky/Karnofsky performance score greater than or equal to 40

          -  Patients must have an unrelated adult bone marrow donor who is Human Leukocyte Antigen
             (HLA)-matched at 8 of 8 HLA-A, -B, -C and -DRB1 at high resolution using DNA-based
             typing.

          -  Patients with adequate physical function: a)Cardiac: Left ventricular ejection
             fraction (LVEF) greater than 40%, or LV shortening fraction greater than 26%; b)
             Pulmonary: Pulse oxymetry with a baseline O2 saturation of greater than or equal to
             85% is required for all patients, Carbon Monoxide Diffusing Capacity (DLCO) greater
             than 40% (corrected for hemoglobin) for patients in whom pulmonary function testing
             can be performed; c) Renal: Serum creatinine less than or equal to 1.5 x upper limit
             of normal for age and glomerular filtration rate (GFR) greater than 100 mL/min/1.73 m.
             For patients older than or equal to 16 years of age, GFR should be greater than 70
             mL/min/1.73 m^2; d) Hepatic: Serum conjugated (direct) bilirubin less than 2x upper
             limit of normal for age as per local laboratory; alanine transaminase (ALT) and
             aspartate transaminase (AST) less than 5 times upper limit of normal as per local
             laboratory.

          -  If the patient has been receiving chronic transfusion therapy for more than or equal
             to 1 year AND has clinical evidence of iron overload (serum ferritin level of greater
             than 1000 ng/ml), a liver biopsy shall be obtained within 90 days of starting
             conditioning therapy (alemtuzumab). Histologic exam of the liver must document absence
             of bridging fibrosis or cirrhosis of the liver. In other cases, a liver biopsy is
             optional.

          -  Hemoglobin S (Hb S) level less than or equal to 45%, seven days prior to initiation of
             alemtuzumab

        Exclusion Criteria:

          -  Evidence of uncontrolled bacterial, viral or fungal infections (currently taking
             medication and progression of clinical symptoms) within 1 month prior to starting the
             conditioning regimen. Patients with fever or suspected minor infection should await
             resolution of symptoms before starting the conditioning regimen

          -  Pregnant or breastfeeding

          -  Patients with 8/8 HLA-matched family donors able to donate

          -  Seropositivity for HIV

          -  Prior allogeneic marrow or stem cell transplant

          -  Iron chelation must be discontinued more than or equal to 48 hours before initiating
             the conditioning regimen

          -  Hydroxyurea (if receiving this therapy) must be discontinued more than or equal to 48
             hours before initiating the conditioning regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Horowitz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Center for International Blood and Marrow Transplant Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of New Orleans/LSUMC CCOP</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University, St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cohen Children's Hospital</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Hospital at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmtctn.net/</url>
    <description>Click here for the Blood and Marrow Transplant Clinical Trials Network Web site</description>
  </link>
  <link>
    <url>https://bethematch.org/</url>
    <description>Click here for the National Marrow Donor Program Web site</description>
  </link>
  <reference>
    <citation>Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56.</citation>
    <PMID>16338616</PMID>
  </reference>
  <reference>
    <citation>Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995 Jun;15(6):825-8. Review.</citation>
    <PMID>7581076</PMID>
  </reference>
  <results_reference>
    <citation>Shenoy S, Eapen M, Panepinto JA, Logan BR, Wu J, Abraham A, Brochstein J, Chaudhury S, Godder K, Haight AE, Kasow KA, Leung K, Andreansky M, Bhatia M, Dalal J, Haines H, Jaroscak J, Lazarus HM, Levine JE, Krishnamurti L, Margolis D, Megason GC, Yu LC, Pulsipher MA, Gersten I, DiFronzo N, Horowitz MM, Walters MC, Kamani N. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016 Nov 24;128(21):2561-2567. Epub 2016 Sep 13.</citation>
    <PMID>27625358</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2008</study_first_submitted>
  <study_first_submitted_qc>August 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2008</study_first_posted>
  <results_first_submitted>August 23, 2017</results_first_submitted>
  <results_first_submitted_qc>November 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 26, 2017</results_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Sickle Cell Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled between August 2008 and April 2014 from 19 different transplant centers.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Bone Marrow Transplant with GVHD Prophylaxis Regimen</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Bone Marrow Transplant with GVHD Prophylaxis Regimen</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14" lower_limit="6" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Indications for Transplant</title>
          <description>Some patients had more than 1 indication</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trans cranial doppler velocity &gt; 200cm/s</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute chest syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaso-occlusive pain crisis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic Blood Transfusion Prior to Transplant</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Score</title>
          <description>Assesses patient self-perceived global quality of life and functioning on a scale of 0 - 100; where 100 equals normal quality of life with no evidence of disease, 90 equals ability to carry on normal activity with minor signs/symptoms of disease, 80 equals normal activity with effort and some signs/symptoms of disease, and 70 equals ability to care for oneself but unable to carry on normal activity or to do active work.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cytomegalovirus (CMV) Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>CMV - donor and recipient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMV + donor and recipient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMV - donor and CMV + recipient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMV + donor and CMV - recipient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Blood Type Match</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>ABO Blood group matched</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABO Blood group major mismatch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABO Blood group minor mismatch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Gender Match</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Gender matched transplants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female donor, male recipient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male donor, female recipient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" lower_limit="21" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Race/Ethnicity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiracial</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Event-Free Survival (EFS)</title>
        <description>EFS is defined as percentage of participants that have not had an event. Primary or secondary graft rejection, disease recurrence, or death will count as events for this endpoint.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Bone Marrow Transplant with GVHD Prophylaxis Regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Event-Free Survival (EFS)</title>
          <description>EFS is defined as percentage of participants that have not had an event. Primary or secondary graft rejection, disease recurrence, or death will count as events for this endpoint.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="56" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="48" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Overall Survival (OS)</title>
        <description>OS is defined as the percentage of participants that have not died.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Bone Marrow Transplant with GVHD Prophylaxis Regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Overall Survival (OS)</title>
          <description>OS is defined as the percentage of participants that have not died.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="67" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="59" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutrophil and Platelet Recovery</title>
        <description>Time to neutrophil recovery is defined as the time of the first of three measurements on consecutive days where the patient has an absolute neutrophil count of &gt;= 500/uL following conditioning regimen induced nadir. Time to platelet recovery is defined as the time of the first of three measurements on consecutive days where the patient has achieved a platelet count &gt; 50,000/uL and is platelet transfusion independent for a minimum of seven days following conditioning regimen induced nadir.</description>
        <time_frame>Up to 100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Bone Marrow Transplant with GVHD Prophylaxis Regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Neutrophil and Platelet Recovery</title>
          <description>Time to neutrophil recovery is defined as the time of the first of three measurements on consecutive days where the patient has an absolute neutrophil count of &gt;= 500/uL following conditioning regimen induced nadir. Time to platelet recovery is defined as the time of the first of three measurements on consecutive days where the patient has achieved a platelet count &gt; 50,000/uL and is platelet transfusion independent for a minimum of seven days following conditioning regimen induced nadir.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutrophil Recovery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="6" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Recovery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="7" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Rejection</title>
        <description>Primary graft rejection is defined as the presence of less than 20% donor cells as assessed by peripheral blood or bone marrow chimerism assays on or after Day 42. Secondary graft rejection is defined as the presence of less than 20% donor derived hematopoietic cells in peripheral blood or bone marrow that occurs after prior evidence of 20% or greater donor cells.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Bone Marrow Transplant with GVHD Prophylaxis Regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Rejection</title>
          <description>Primary graft rejection is defined as the presence of less than 20% donor cells as assessed by peripheral blood or bone marrow chimerism assays on or after Day 42. Secondary graft rejection is defined as the presence of less than 20% donor derived hematopoietic cells in peripheral blood or bone marrow that occurs after prior evidence of 20% or greater donor cells.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary Graft Rejection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary Graft Rejection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Acute Graft-vs-Host-Disease (GVHD)</title>
        <description>Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:
Skin stage:
0: No rash
Rash &lt;25% of body surface area
Rash on 25-50% of body surface area
Rash on &gt; 50% of body surface area
Generalized erythroderma with bullous formation
Liver stage (based on bilirubin level)*:
0: &lt;2 mg/dL
2-3 mg/dL
3.01-6 mg/dL
6.01-15.0 mg/dL
&gt;15 mg/dL
GI stage*:
0: No diarrhea or diarrhea &lt;500 mL/day
Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD
Diarrhea 1000-1499 mL/day
Diarrhea &gt;1500 mL/day
Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.
GVHD grade:
0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Bone Marrow Transplant with GVHD Prophylaxis Regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Acute Graft-vs-Host-Disease (GVHD)</title>
          <description>Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:
Skin stage:
0: No rash
Rash &lt;25% of body surface area
Rash on 25-50% of body surface area
Rash on &gt; 50% of body surface area
Generalized erythroderma with bullous formation
Liver stage (based on bilirubin level)*:
0: &lt;2 mg/dL
2-3 mg/dL
3.01-6 mg/dL
6.01-15.0 mg/dL
&gt;15 mg/dL
GI stage*:
0: No diarrhea or diarrhea &lt;500 mL/day
Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD
Diarrhea 1000-1499 mL/day
Diarrhea &gt;1500 mL/day
Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.
GVHD grade:
0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade II-IV Acute GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="13" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade III-IV Acute GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="6" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Chronic GVHD</title>
        <description>Chronic GVHD is defined per NIH 2005 Consensus Criteria.</description>
        <time_frame>1 year post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Bone Marrow Transplant with GVHD Prophylaxis Regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Chronic GVHD</title>
          <description>Chronic GVHD is defined per NIH 2005 Consensus Criteria.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="41" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Chronic GVHD by Severity</title>
        <description>Chronic GVHD severity is defined per NIH 2005 Consensus Criteria.</description>
        <time_frame>1 year post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Bone Marrow Transplant with GVHD Prophylaxis Regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Chronic GVHD by Severity</title>
          <description>Chronic GVHD severity is defined per NIH 2005 Consensus Criteria.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Posterior Reversible Encephalopathy Syndrome (PRES)</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Bone Marrow Transplant with GVHD Prophylaxis Regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Posterior Reversible Encephalopathy Syndrome (PRES)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="18" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 100 in Participant Reported Health-Related Quality of Life (HRQL)</title>
        <description>HRQL will be assessed using the Self-Esteem, General Health Perception, and Change in Health subscales of the Child Health Questionnaire (CHQ Child Form 87). The changes in participant reported scores on these HRQL subscales from a pre-transplant baseline assessment to day 100 post-transplant will be evaluated. Each subscale is scored is scored in the range 0-100, with higher scores indicating better health and well-being. Therefore, a negative mean change in score denotes worsening HRQL score and positive mean change in score denotes an improved HRQL score over time.</description>
        <time_frame>100 days post-transplant</time_frame>
        <population>Participants age 10 years or older that returned the HRQL surveys</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Bone Marrow Transplant with GVHD Prophylaxis Regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 100 in Participant Reported Health-Related Quality of Life (HRQL)</title>
          <description>HRQL will be assessed using the Self-Esteem, General Health Perception, and Change in Health subscales of the Child Health Questionnaire (CHQ Child Form 87). The changes in participant reported scores on these HRQL subscales from a pre-transplant baseline assessment to day 100 post-transplant will be evaluated. Each subscale is scored is scored in the range 0-100, with higher scores indicating better health and well-being. Therefore, a negative mean change in score denotes worsening HRQL score and positive mean change in score denotes an improved HRQL score over time.</description>
          <population>Participants age 10 years or older that returned the HRQL surveys</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Self esteem score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health perception score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.90" spread="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in health score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 100 in Parent Proxy Reported Health-Related Quality of Life (HRQL)</title>
        <description>HRQL will be assessed using the Self-Esteem, General Health Perception, and Change in Health subscales of the Child Health Questionnaire (CHQ Child Form 87). The changes in parent proxy reported scores on these HRQL subscales from a pre-transplant baseline assessment to day 100 post-transplant will be evaluated. Each subscale is scored is scored in the range 0-100, with higher scores indicating better health and well-being. Therefore, a negative mean change in score denotes worsening HRQL score and positive mean change in score denotes an improved HRQL score over time.</description>
        <time_frame>100 days post-transplant</time_frame>
        <population>Parent proxies of participants that returned the HRQL surveys</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Bone Marrow Transplant with GVHD Prophylaxis Regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 100 in Parent Proxy Reported Health-Related Quality of Life (HRQL)</title>
          <description>HRQL will be assessed using the Self-Esteem, General Health Perception, and Change in Health subscales of the Child Health Questionnaire (CHQ Child Form 87). The changes in parent proxy reported scores on these HRQL subscales from a pre-transplant baseline assessment to day 100 post-transplant will be evaluated. Each subscale is scored is scored in the range 0-100, with higher scores indicating better health and well-being. Therefore, a negative mean change in score denotes worsening HRQL score and positive mean change in score denotes an improved HRQL score over time.</description>
          <population>Parent proxies of participants that returned the HRQL surveys</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Self esteem scale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.12" spread="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health perception score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.13" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in health score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 180 in Participant Reported Health-Related Quality of Life (HRQL)</title>
        <description>HRQL will be assessed using the Self-Esteem, General Health Perception, and Change in Health subscales of the Child Health Questionnaire (CHQ Child Form 87). The changes in participant reported scores on these HRQL subscales from a pre-transplant baseline assessment to day 180 post-transplant will be evaluated. Each subscale is scored is scored in the range 0-100, with higher scores indicating better health and well-being. Therefore, a negative mean change in score denotes worsening HRQL score and positive mean change in score denotes an improved HRQL score over time.</description>
        <time_frame>180 days post-transplant</time_frame>
        <population>Participants age 10 years or older that returned the HRQL surveys</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Bone Marrow Transplant with GVHD Prophylaxis Regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 180 in Participant Reported Health-Related Quality of Life (HRQL)</title>
          <description>HRQL will be assessed using the Self-Esteem, General Health Perception, and Change in Health subscales of the Child Health Questionnaire (CHQ Child Form 87). The changes in participant reported scores on these HRQL subscales from a pre-transplant baseline assessment to day 180 post-transplant will be evaluated. Each subscale is scored is scored in the range 0-100, with higher scores indicating better health and well-being. Therefore, a negative mean change in score denotes worsening HRQL score and positive mean change in score denotes an improved HRQL score over time.</description>
          <population>Participants age 10 years or older that returned the HRQL surveys</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Self esteem scale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.33" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health perception score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.69" spread="4.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in health score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 180 in Parent Proxy Reported Health-Related Quality of Life (HRQL)</title>
        <description>HRQL will be assessed using the Self-Esteem, General Health Perception, and Change in Health subscales of the Child Health Questionnaire (CHQ Child Form 87). The changes in parent proxy reported scores on these HRQL subscales from a pre-transplant baseline assessment to day 180 post-transplant will be evaluated. Each subscale is scored is scored in the range 0-100, with higher scores indicating better health and well-being. Therefore, a negative mean change in score denotes worsening HRQL score and positive mean change in score denotes an improved HRQL score over time.</description>
        <time_frame>180 days post-transplant</time_frame>
        <population>Parent proxies of participants that returned the HRQL surveys</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Bone Marrow Transplant with GVHD Prophylaxis Regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 180 in Parent Proxy Reported Health-Related Quality of Life (HRQL)</title>
          <description>HRQL will be assessed using the Self-Esteem, General Health Perception, and Change in Health subscales of the Child Health Questionnaire (CHQ Child Form 87). The changes in parent proxy reported scores on these HRQL subscales from a pre-transplant baseline assessment to day 180 post-transplant will be evaluated. Each subscale is scored is scored in the range 0-100, with higher scores indicating better health and well-being. Therefore, a negative mean change in score denotes worsening HRQL score and positive mean change in score denotes an improved HRQL score over time.</description>
          <population>Parent proxies of participants that returned the HRQL surveys</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Self esteem scale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.46" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health perception score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.63" spread="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in health score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 1 Year in Participant Reported Health-Related Quality of Life (HRQL)</title>
        <description>HRQL will be assessed using the Self-Esteem, General Health Perception, and Change in Health subscales of the Child Health Questionnaire (CHQ Child Form 87). The changes in participant reported scores on these HRQL subscales from a pre-transplant baseline assessment to 1 year post-transplant will be evaluated. Each subscale is scored is scored in the range 0-100, with higher scores indicating better health and well-being. Therefore, a negative mean change in score denotes worsening HRQL score and positive mean change in score denotes an improved HRQL score over time.</description>
        <time_frame>1 year post-transplant</time_frame>
        <population>Participants age 10 years or older that returned the HRQL surveys</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Bone Marrow Transplant with GVHD Prophylaxis Regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 1 Year in Participant Reported Health-Related Quality of Life (HRQL)</title>
          <description>HRQL will be assessed using the Self-Esteem, General Health Perception, and Change in Health subscales of the Child Health Questionnaire (CHQ Child Form 87). The changes in participant reported scores on these HRQL subscales from a pre-transplant baseline assessment to 1 year post-transplant will be evaluated. Each subscale is scored is scored in the range 0-100, with higher scores indicating better health and well-being. Therefore, a negative mean change in score denotes worsening HRQL score and positive mean change in score denotes an improved HRQL score over time.</description>
          <population>Participants age 10 years or older that returned the HRQL surveys</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Self esteem scale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.97" spread="5.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health perception score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.99" spread="6.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in health score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 1 Year in Parent Proxy Reported Health-Related Quality of Life (HRQL)</title>
        <description>HRQL will be assessed using the Self-Esteem, General Health Perception, and Change in Health subscales of the Child Health Questionnaire (CHQ Child Form 87). The changes in parent proxy reported scores on these HRQL subscales from a pre-transplant baseline assessment to 1 year post-transplant will be evaluated. Each subscale is scored is scored in the range 0-100, with higher scores indicating better health and well-being. Therefore, a negative mean change in score denotes worsening HRQL score and positive mean change in score denotes an improved HRQL score over time.</description>
        <time_frame>1 year post-transplant</time_frame>
        <population>Parent proxies of participants that returned the HRQL surveys</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Bone Marrow Transplant with GVHD Prophylaxis Regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 1 Year in Parent Proxy Reported Health-Related Quality of Life (HRQL)</title>
          <description>HRQL will be assessed using the Self-Esteem, General Health Perception, and Change in Health subscales of the Child Health Questionnaire (CHQ Child Form 87). The changes in parent proxy reported scores on these HRQL subscales from a pre-transplant baseline assessment to 1 year post-transplant will be evaluated. Each subscale is scored is scored in the range 0-100, with higher scores indicating better health and well-being. Therefore, a negative mean change in score denotes worsening HRQL score and positive mean change in score denotes an improved HRQL score over time.</description>
          <population>Parent proxies of participants that returned the HRQL surveys</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Self esteem scale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.61" spread="6.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health perception score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.89" spread="5.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in health score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years post-transplant</time_frame>
      <desc>Serious Adverse Events (AE) are defined as events associated with death, life-threatening event, disability, congenital anomaly, required intervention to prevent permanent impairment or damage, hospitalization or other serious adverse event. Only unexpected grades 3-5 adverse events were required to be reported through the AE system per protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Bone Marrow Transplant with GVHD Prophylaxis Regimen</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune haemolytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Mendizabal, PhD</name_or_title>
      <organization>The Emmes Corporation</organization>
      <phone>301-251-1161</phone>
      <email>amendizabal@emmes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

